Table 3

Phase I versus Phase II patient development of antibodies to retroviral envelope proteinsa

Antibody titersNeutralizing antibodies
Day 0Day 30Day 60Day 90PlasmaPeritoneal fluid
Phase I patient nos.
 100
 2000Negative
 30022>740+Negative
 400
 500
 6006722NegativeNegative
 7000NegativeNegative
 8000
 90022NegativeNegative
 1000
 110220NegativeNegative
 1200
  Summary0 of 12 (0%)1 of 12 (8.3%)3 of 7 (43%)2 of 2 (100%)1 of 5 (20%)0 of 6 (0%)
Phase II patient nos.
 1067>740+Negative
 20022NegativeNegative
 3067
 400200740+Negative
 5740200740++
 667200++
  Summary2 of 6 (33%)4 of 6 (66%)4 of 4 (100%)1 of 1 (100%)4 of 5 (80%)2 of 5 (40%)
  • a P = 0.025 (comparison of percentage antibody development, Phase I versus Phase II, on day 60).